Novartis is aiming to distinguish new psoriasis med Cosentyx from the rest of the next-gen field by building up its label, adding nods for conditions including ankylosing spondylitis. But it'll have some competition in that space, too.
FiercePharmaAsia combs earnings calls by major drug companies for notable and quotable nuggets on emerging markets and Asia to track the latest sales trends and insight into business outlooks in markets as diverse as China, India and Japan to Southeast Asia.
Social media success in consumer marketing has advanced beyond counting fans and followers. Today it's all about shares, retweets and links that indicate real consumer engagement with brands....
With all the excitement about Novartis' new heart failure drug Entresto, the usual question that follows an FDA approval--how will they actually sell it--might seem irrelevant. But the former LCZ696's path to blockbuster sales isn't without its obstacles, and the Swiss drugmaker isn't leaving much to chance.
Novartis CEO Joe Jimenez said in March the company would have another go at significant cost cuts in the wake of its asset swap with GlaxoSmithKline. Manufacturing was one area where it expected to tighten up, and a plant in India is now on the chopping block along with 170 jobs.
Novartis has opened a new front in its push into digital health. The latest move sees the Big Pharma bring its navigation app for visually impaired people to Apple and Google's smartwatch platforms.
Multinational drug firms in Australia faced a string of barbs in hearings held by a Senate panel into transfer pricing that included a reference to a fictitious German World War II prison camp guard.
Kickback allegations against Novartis just got scarier. After years of investigating the Swiss drugmaker, the Justice Department and 11 states are demanding almost $3.4 billion in damages and fines in a False Claims Act lawsuit nearing trial.
We checked and everything is done correctly on our tax obligations, 9 drug companies said in separate submissions ahead of testimony on July 1 to an Australian Senate inquiry on tax avoidance.
Novartis snapped up tiny Spinifex and its mid-stage pain drug in a $200 million-plus deal.